PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
2.18%
Revenue growth near Drug Manufacturers - Specialty & Generic median of 2.18%. Charlie Munger would verify if industry-standard growth is attractive.
19.31%
Cost growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 4.25%. Jim Chanos would check for structural cost disadvantages.
-22.45%
Gross profit decline while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate competitive position.
-24.11%
Margin decline while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate competitive position.
-21.64%
R&D reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate competitive implications.
-4.92%
G&A reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate efficiency gains.
26.68%
Marketing expense change of 26.68% versus flat Drug Manufacturers - Specialty & Generic spending. Walter Schloss would verify adequacy.
-196.11%
Other expenses reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate advantages.
1.34%
Operating expenses growth below 50% of Drug Manufacturers - Specialty & Generic median of 6.61%. Joel Greenblatt would investigate efficiency.
12.78%
Total costs growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 7.00%. Jim Chanos would check for waste.
-3.55%
Interest expense reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate advantages.
-59.60%
D&A reduction while Drug Manufacturers - Specialty & Generic median is 0.95%. Seth Klarman would investigate efficiency.
-345.70%
EBITDA decline while Drug Manufacturers - Specialty & Generic median is -5.86%. Seth Klarman would investigate causes.
23.03%
Margin change of 23.03% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify quality.
-866.94%
Operating income decline while Drug Manufacturers - Specialty & Generic median is -5.05%. Seth Klarman would investigate causes.
-850.60%
Operating margin decline while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate causes.
-248.96%
Other expenses reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate advantages.
-969.84%
Pre-tax income decline while Drug Manufacturers - Specialty & Generic median is -12.31%. Seth Klarman would investigate causes.
-951.31%
Pre-tax margin decline while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate causes.
-137.19%
Tax expense reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate advantages.
-1775.75%
Net income decline while Drug Manufacturers - Specialty & Generic median is -8.80%. Seth Klarman would investigate causes.
-1740.06%
Net margin decline while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate causes.
-1785.39%
EPS decline while Drug Manufacturers - Specialty & Generic median is -2.14%. Seth Klarman would investigate causes.
-1785.39%
Diluted EPS decline while Drug Manufacturers - Specialty & Generic median is -2.27%. Seth Klarman would investigate causes.
11.26%
Share count change of 11.26% versus stable Drug Manufacturers - Specialty & Generic. Walter Schloss would verify approach.
11.07%
Diluted share change of 11.07% versus stable Drug Manufacturers - Specialty & Generic. Walter Schloss would verify approach.